Chloramphenicol - Generic Drug Details

What are the generic sources for chloramphenicol and what is the scope of patent protection?

Chloramphenicol is the generic ingredient in fourteen branded drugs marketed by Parke Davis, Parkedale, Altana, Pharmafair, Allergan, Alcon, Epic Pharma Llc, Optopics, Elkins Sinn, Fresenius Kabi Usa, Gruppo Lepetit, and Angus, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for chloramphenicol.

Summary for chloramphenicol

US Patents:	0
Tradenames:	14
Applicants:	12
NDAs:	25
Drug Master File Entries:	14
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	18
Drug Prices:	Drug price trends for chloramphenicol
DailyMed Link:	chloramphenicol at DailyMed

See drug prices for chloramphenicol

Recent Clinical Trials for chloramphenicol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit	Phase 2/Phase 3
Mahidol Oxford Tropical Medicine Research Unit	Phase 2/Phase 3
King's College London	N/A

See all chloramphenicol clinical trials

Medical Subject Heading (MeSH) Categories for chloramphenicol

Anti-Bacterial Agents

Protein Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for chloramphenicol

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

D10AF	Antiinfectives for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

G01AA	Antibiotics
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G	Genito-urinary system and sex hormones

J01BA	Amphenicols
J01B	AMPHENICOLS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for chloramphenicol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	CHLOROPTIC	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	050091-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	CHLOROMYCETIN HYDROCORTISONE	chloramphenicol; hydrocortisone acetate	FOR SUSPENSION;OPHTHALMIC	050202-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	OPHTHOCORT	chloramphenicol; hydrocortisone acetate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050201-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Parke Davis	CHLOROMYXIN	chloramphenicol; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050203-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Parkedale	CHLOROMYCETIN	chloramphenicol sodium succinate	INJECTABLE;INJECTION	050155-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Optopics	OPTOMYCIN	chloramphenicol	SOLUTION/DROPS;OPHTHALMIC	062171-001	Mar 31, 1982		DISCN	No	No

Chloramphenicol Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Chloramphenicol?

Chloramphenicol is an antibiotic discovered in 1947, historically used to treat serious bacterial infections. In recent years, its usage has declined considerably due to safety concerns primarily related to bone marrow suppression and aplastic anemia. However, certain markets continue to rely on Chloramphenicol, especially where alternatives are limited or in specific applications.

Regulatory Status and Market Availability

• Global status: Many countries restrict or ban Chloramphenicol for systemic use. The U.S. Food and Drug Administration (FDA) withdrew approval in 1983 due to toxicity risks. The European Medicines Agency (EMA) also recommends restriction.
• Developing markets: Countries like India, China, and parts of Africa permit its use under strict regulations, mostly for ophthalmic and topical formulations.
• Market drivers: The antibiotic's broad spectrum and low cost support continued use in niche markets, especially in regions with limited access to newer antibiotics.

Supply Chain Considerations

• Manufacturing: Synthetic process controls have improved, but production remains limited due to safety concerns.
• Regulations: Stringent regulations limit manufacturing and distribution, impacting supply stability.
• Counterfeit risks: Presence of counterfeit products affects market integrity in parts of Asia and Africa.

Competitive Landscape

• Alternatives: Safer antibiotics like amoxicillin, doxycycline, and third-generation cephalosporins have replaced Chloramphenicol in most developed regions.
• Market share: In ophthalmology, where systemic toxicity is less problematic, Chloramphenicol retains a niche, with global ophthalmic antibiotic sales reaching approximately USD 1.5 billion in 2021 ([1]).

Demand Dynamics

• Current demand: Primarily driven by veterinary uses and ophthalmic products.
• Emerging markets: Growing populations and limited healthcare infrastructure in some regions sustain demand.
• Resistance issues: Bacterial resistance patterns influence usage but are less significant for ophthalmic formulations.

What Is the Financial Trajectory for Chloramphenicol?

Revenue Trends

• Market sales: Estimated global sales for Chloramphenicol-based ophthalmic drugs are roughly USD 100–200 million annually, with no significant growth forecast due to safety concerns and replacement by newer antibiotics.
• Market decline: In developed countries, sales declined over the last two decades from USD 500 million in the late 1990s to current levels.

Production and Investment

• Manufacturing costs: Low due to simple synthesis, but regulatory costs are high, affecting profit margins.
• Research investments: Minimal R&D investment as the drug's reputation limits development enthusiasm.

Regulatory and Patent Impact

• Patents: The original patents have long expired; no recent patent protections exist.
• Regulatory risk: Ongoing restrictions and potential bans in certain jurisdictions threaten future sales.

Future Outlook

• Growth potential: Limited to niche ophthalmic applications and veterinary markets.
• Market risks: Toxicity concerns, regulatory restrictions, and competition from safer antibiotics constrain market expansion.
• Innovation prospects: No significant pipeline exists; research interest remains low.

Summary of Market and Financial Outlook

Aspect	Status	Commentary
Global regulatory status	Restricted or banned in many developed regions	Limits market expansion
Demand drivers	Ophthalmic applications, veterinary use, regional needs	Sustains niche markets
Sales volume	USD 100–200 million annually in ophthalmic segment	No significant growth expected
Market growth	Decline in developed markets; stability in select regions	Decline driven by safety concerns and alternatives
Investment potential	Very low; R&D minimal	High regulatory barriers and safety issues limit innovation

Key Takeaways

• Chloramphenicol's market is shrinking in developed countries due to safety risks.
• Niche applications, especially ophthalmologic, sustain some demand.
• The financial trajectory shows declining sales with no significant growth prospects.
• Regulatory restrictions pose a high barrier for market expansion and new product formulation.
• Limited R&D interest indicates a long-term decline trend.

FAQs

1. Why has Chloramphenicol's use declined in most markets?
Safety concerns, including rare but severe side effects like aplastic anemia, led to regulatory restrictions and replacement by newer antibiotics.

2. In which regions does Chloramphenicol still have a significant market?
Developing countries such as India, China, and certain African nations maintain limited use, mainly for topical or ophthalmic formulations.

3. What are the main competition challenges facing Chloramphenicol?
Safer antibiotics with fewer side effects and better resistance profiles dominate the market, leaving Chloramphenicol with minimal applications.

4. How does regulatory risk affect the future of Chloramphenicol?
Ongoing restrictions and potential bans in some jurisdictions threaten its manufacturing, distribution, and overall market viability.

5. Are there any ongoing developments or innovations for Chloramphenicol?
No significant pipeline exists; most interest has waned due to safety issues and market competition.

---

References

[1] IQVIA, "Ophthalmic Antibiotics Market Analysis," 2022.